Statins in homozygous familial hypercholesterolemia

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Current Atherosclerosis Reports

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11883-002-0058-7PMID 11772418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Cholesterol Quartet

  2001cited by this paper
• Autosomal Recessive Hypercholesterolemia Caused by Mutations in a Putative LDL Receptor Adaptor Protein

  2001cited by this paper
• The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.

  2000cited by this paper
• Therapy with statins is effective in some patients with homozygous familial hypercholesterolemia.

  2000cited by this paper
• The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy

  2000cited by this paper
• Clinical outcome of patients with familial hypercholesterolemia and coronary artery disease undergoing partial ileal bypass surgery.

  2000cited by this paper
• Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.

  2000cited by this paper
• Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia.

  1999cited by this paper
• Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E.

  1999cited by this paper
• Effects of atorvastatin in patients with homozygous familial hypercholesterolemia.

  1999cited by this paper
• An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits.

  1998cited by this paper
• Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.

  1997cited by this paper
• Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.

  1997cited by this paper
• Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.

  1997cited by this paper
• Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B‐100

  1996cited by this paper
• Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

  1995cited by this paper
• The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100.

  1995cited by this paper
• Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia

  1994cited by this paper
• Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor.

  1993cited by this paper
• Treatment of homozygous familial hypercholesterolemia by plasma exchange and LDL-apheresis.

  1993cited by this paper
• Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100.

  1993cited by this paper
• Plasma exchange for homozygous familial hypercholesterolaemia: the Cape Town experience.

  1993cited by this paper
• Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia.

  1993cited by this paper
• The discovery and development of HMG-CoA reductase inhibitors.

  1992cited by this paper
• Low-density lipoprotein plasmaphaeresis with and without lovastatin in the treatment of the homozygous form of familial hypercholesterolaemia

  1990cited by this paper
• Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover.

  1988cited by this paper
• The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway.

  1987cited by this paper
• Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia.

  1986cited by this paper
• Effects of probucol on homozygous cases of familial hypercholesterolemia.

  1983cited by this paper
• Portacaval shunt in patients with familial hypercholesterolemia.

  1983cited by this paper
• Treatment of homozygous familial hypercholesterolaemia with probucol.

  1982cited by this paper
• Therapeutic effects of ML-236B in primary hypercholesterolemia.

  1980cited by this paper
• A host of hypercholesterolaemic homozygotes in South Africa.

  1980cited by this paper

• Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Homozygous Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Efficacy and Safety.

  2025cites this paper
• Treatment of Homozygous Familial Hypercholesterolemia

  2025cites this paper
• Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary.

  2024cites this paper
• Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis.

  2023cites this paper
• Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia

  2022cites this paper
• Regulatory Non-Coding RNAs in Familial Hypercholesterolemia, Theranostic Applications

  2022cites this paper
• A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients

  2022cites this paper
• UNMET MEDICAL NEEDS IN HIGH-RISK CARDIOVASCULAR PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

  2021cites this paper
• PCSK9 Inhibitor Induces a Transient Decrease in Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio in Homozygous/Compound Heterozygous Familial Hypercholesterolemia Patients

  2021cites this paper
• Characterization of novel stress degradation products of Bempedoic acid and Ezetimibe using UPLC–MS/MS: development and validation of stability-indicating UPLC method

  2021cites this paper
• Lipoprotein metabolism in familial hypercholesterolemia

  2021cites this paper
• Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting.

  2020cites this paper
• Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives

  2019cites this paper
• Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis

  2019cites this paper
• Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2

  2017cites this paper
• Atypical Presentation and Treatment Response in a Child with Familial Hypercholesterolemia Having a Novel LDLR Mutation.

  2016cites this paper
• Hipercolesterolemia familiar homocigota: adaptación a España del documento de posición del grupo de consenso sobre hipercolesterolemia familiar de la Sociedad Europea de Arteriosclerosis. Documento de Consenso de la Sociedad Española de Arteriosclerosis (SEA) y la Fundación Hipercolesterolemia Famil

  2015cites this paper
• The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.

  2015cites this paper
• [Homozygous familial hypercholesterolaemia: Spanish adaptation of the position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Consensus document of the Spanish Society of Arteriosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (

  2015cites this paper
• Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.

  2015cites this paper
• Homozigot ailevi hiperkolesterolemi: klinisyenlerin taniyi ve klinik yönetimi gelistirmelerine yönelik yeni anlayislar ve rehberlik. Avrupa Ateroskleroz Dernegi'nin Ailevi Hiperkolesterolemi Üzerine Uzlasi Paneli yazili görüsü.

  2015cites this paper
• [Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society].

  2015cites this paper
• [New lipid lowering agents].

  2014cites this paper
• Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

  2014cites this paper
• Treatment of homozygous familial hypercholesterolemia

  2014cites this paper
• Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.

  2014cites this paper
• What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?

  2014cites this paper
• Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.

  2014cites this paper
• Nuevos fármacos para el tratamiento de la hipercolesterolemia

  2014cites this paper
• Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances

  2014cites this paper
• Current Treatment of Famil ial Hypercholesterolaemia

  2014cites this paper
• Current Treatment of Familial Hypercholesterolaemia.

  2014cites this paper
• Lomitapide: a novel drug for homozygous familial hypercholesterolemia

  2014cites this paper
• Lomitapide: A Review of its Use in Adults with Homozygous Familial Hypercholesterolemia

  2013cites this paper
• Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.

  2012cites this paper
• Role of apheresis in the management of familial hypercholesterolemia and elevated Lp(a) levels

  2011cites this paper
• Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

  2011cites this paper
• Psychological Issues in Genetic Testing for Inherited Cardiovascular Diseases

  2011cites this paper
• Hyperlipidaemia in Paediatric Patients

  2010cites this paper
• A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.

  2008cites this paper
• Inherited metabolic disorders and cerebral infarction

  2008cites this paper
• Procédés de modulation des niveaux de lipoprotéine et cholestérol chez l'homme

  2005cites this paper
• Homozygous Familial Hypercholesterolemia and Its Management

  2004cites this paper
• Current management of severe homozygous hypercholesterolaemias

  2004cites this paper
• In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis?

  2004cites this paper
• [Pharmacological interactions of statins].

  2003cites this paper
• Interacciones farmacológicas de las estatinas

  2003cites this paper
• Reduction in Mortality in Subjects with Homozygous Familial Hypercholesterolemia Associated with Advances in Lipid-lowering Therapy Clinical Perspective on P ●●● Determination of Hofh Gene Mutations Lipid Profiles Major Adverse Cardiovascular Events Statistical Analysis Results Clinical Characterist

  year unknowncites this paper